Correspondence 0001493152-24-030938 from Q/C TECHNOLOGIES, INC. (QCLS)
Q/C TECHNOLOGIES, INC.
Date: Aug. 9, 2024 · CIK: 0001321834 · Accession: 0001493152-24-030938
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280415
Letter
TNF Pharmaceuticals, Inc.
N. Wolfe Street, Suite 623
Baltimore, MD 21205
August 9, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Attention: Tamika Sheppard
Re: TNF Pharmaceuticals, Inc. (f/k/a MyMD Pharmaceuticals, Inc.)
Registration Statement on Form S-3
Originally filed on June 21, 2024, as amended on August 8, 2024
File No. 333-280415 (as amended, the “Registration Statement”)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, TNF Pharmaceuticals, Inc., formally known as MyMD Pharmaceuticals, Inc. (the “Company”), hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on August 12, 2024, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Alla Digilova, Esq. at (212) 659-4993.
Very
truly yours,
TNF
Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
TNF
Pharmaceuticals, Inc.
855
N. Wolfe Street, Suite 623
Baltimore,
MD 21205
August
9, 2024
VIA
EDGAR
Division
of Corporation Finance
Office
of Life Sciences
U.S.
Securities and Exchange Commission
Washington,
D.C. 20549
Attention:
Tamika
Sheppard
Re:
TNF
Pharmaceuticals, Inc. (f/k/a MyMD Pharmaceuticals, Inc.)
Registration
Statement on Form S-3
Originally
filed on June 21, 2024, as amended on August 8, 2024
File
No. 333-280415 (as amended, the “Registration Statement”)
Request
for Acceleration
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under
the Securities Act of 1933, as amended, TNF Pharmaceuticals, Inc., formally known as MyMD Pharmaceuticals, Inc. (the “Company”),
hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:30
p.m., Eastern Time, on August 12, 2024, or as soon thereafter as practicable.
Should
any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes
and Boone, LLP, attention: Alla Digilova, Esq. at (212) 659-4993.
Very
truly yours,
TNF
Pharmaceuticals, Inc.
By:
/s/
Joshua Silverman
Joshua
Silverman
Chaiman
of the Board
cc:
Alla
Digilova, Esq., Haynes and Boone, LLP